ANNUAL multi-cancer early detection screening reduces stage IV diagnoses and emergency presentations in randomized clinical trials. Data presented from the landmark randomized controlled trial evaluating blood-based multi-cancer early detection screening demonstrated that adding yearly cell-free DNA blood testing to standard screening protocols significantly alters the clinical timing of cancer identification.
Although the landmark trial did not achieve its primary endpoint of a statistically significant reduction in combined late-stage diagnoses across twelve prespecified cancer types, encouraging downstaging trends were observed over the three-year study period. Patients receiving annual multi-cancer early detection screening experienced a 14% reduction in stage IV diagnoses alongside a 19% increase in cancers diagnosed at earlier stages. Importantly, the prespecified list excluded malignancies with existing routine screening programs, such as breast and cervical cancers.
Multi-cancer early detection screening also yielded substantial clinical improvements in how individuals entered the healthcare pathway. Across all malignancy types, cancers detected clinically due to symptoms decreased by 21%, while emergency presentation diagnoses dropped by 25% compared to standard screening alone. Because emergency presentations typically involve advanced malignancies with poorer clinical prognoses, shifting initial detection to asymptomatic screening represents a major operational advantage for routine clinical practice.
Proactive testing with multi-cancer early detection screening identified four times as many cancers through screening compared to standard protocols alone, capturing 1,173 cases in the intervention arm versus 290 cases in the control arm. The cell-free DNA assay demonstrated an exceptionally high specificity of 99.55% and a positive predictive value of 52%. When a positive cancer signal was detected, the blood test accurately predicted the underlying primary tissue site of origin in 87% of single-site predictions and 92.5% of top two predictions.
While extended participant follow-up remains necessary to determine long-term overall survival benefits and cost effectiveness, these initial findings demonstrate that multi-cancer early detection screening is clinically feasible at scale within health systems and effectively shifts cancer identification toward earlier stages.
Reference
Swanton C et al. Galleri early detection test may shift timing of cancer detection, reducing stage IV diagnoses. ASCO. 2026.
Featured Image: Daniel Chetroni on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
